Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Corp., a biotechnology company focused on discovering and developing aptamers, announced the successful completion of a Phase 1 study of its novel aptamer therapeutic, ARC1779. ARC1779 is designed to selectively block the activation, adhesion and aggregation of platelets by inhibiting the binding of von Willebrand Factor (vWF) to the GPIb receptor on platelets. Activated vWF is scientifically recognized as the first stage of arterial thrombus formation and plays a significant role in the development of harmful blood clots. Archemix plans to develop ARC1779 as an anti-thrombotic drug for use in angioplasty and in a rare blood disorder that is mediated by vWF known as thrombotic thrombocytopenic purpura, or TTP.

Archemix plans to present a complete data set from this Phase 1 clinical trial within a peer-reviewed forum in 2007.

Based on the proof-of-mechanism data from this Phase 1 study, Archemix plans to commence a Phase 2 study of ARC1779 to evaluate the safety and efficacy of ARC1779 in acute coronary syndrome patients during the fourth quarter of 2007. Additionally, Archemix plans to initiate a Phase 1b study of ARC1779 in patients suffering from TTP in the fourth quarter of 2007. Approximately 3,000 new cases of TTP are diagnosed per year in the United States, but currently there is no approved drug therapy for the disease.

"We are very pleased to demonstrate ARC1779 can inhibit vWF activation and platelet function, which are both widely recognized as playing critical roles in clot formation which can critically impede blood flow to the heart," said Jim Gilbert, M.D., Chief Medical Officer, Archemix. "In Phase 2, we hope to show that using ARC1779 during angioplasty may improve myocardial perfusion by reducing blood clots in the coronary microcirculation while also providing effective anti-thrombotic treatment at the primary site of arte
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:5/29/2015)... , May 29, 2015 Educating ... of the Association for the Advancement of Wound ... With support from AAWC,s corporate partners, the ... Portal on the AAWC website at ... wound care pathway with links to various CME/CEU ...
(Date:5/28/2015)... Research and Markets ( ... Jain PharmaBiotech,s new report  "RNAi - Technologies, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... the use of double stranded RNA (dsRNA). ... processed into short 21-23 nucleotide RNAs termed ...
(Date:5/28/2015)... 28, 2015 The controversy surrounding the ... and myomectomies (procedures to remove uterine fibroids) continues, ... is investigating Johnson & Johnson,s Ethicon, Inc. unit, ... devices. According to the report published by The ... the FBI is trying to determine what the ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... 8, 2010 A new analysis of the effects ... enhanced treatment options for tens of millions of people ... from certain food or nutritional supplements but not manufactured ... play a role in optimal brain functioning and have ...
... 7, 2010 Hop-on, Inc. (Pink Sheets: ... about the Appeals Court ruling that the Food and Drug ... of the Food, Drug and Cosmetic Act (according to ... in February 2010 when Federal Judge Leon ruled that the ...
Cached Medicine Technology:Omega-3 Supplements Show Promise in Alleviating Depression 2Hop-on Reports: FDA Cannot Regulate Electronic Cigarettes 2
(Date:5/29/2015)... 29, 2015 Red Hot & Blue ... Red Hot & Blue restaurant at 525 New Waverly Place ... 7, 2015. “The Red Hot & Blue Restaurant was previously ... but we have moved to a new location in the ... middle of all the activities on the Promenade–with outdoor seating ...
(Date:5/29/2015)... May 29, 2015 The Healthcare ... graduates of its Advanced Training Program (ATP) in ... fill roles in their health care organization ranging ... and methodology of continuous quality improvement in the ... to Dr. Brent James’ internationally recognized Advanced Training ...
(Date:5/29/2015)... Inspire Nexus, a new social network officially ... question many life coaches have asked, "How do I ... necessary to become a credentialed Coach?" , Many Life ... for long. Inspire Nexus, a social network for Coaches ... who have experience coaching a certain number of hours, ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The campaign ... well as a number of specific concerns within, including ... reduction and mental health in the workplace. We are ... health. The campaign also brings special focus to people ... to speak up and seek help from healthcare professionals ...
(Date:5/29/2015)... TX (PRWEB) May 29, 2015 ... 2015” provides comprehensive information on the therapeutic development ... types of muscles in the body, leading to ... R&D pipelines by identifying new targets and MOAs ... on H1 2015 pipeline review of Axillary Hyperhidrosis ...
Breaking Medicine News(10 mins):Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:HORNE LLP’s Healthcare Delivery Institute Graduates Class from the Advanced Training Program 2Health News:Mediaplanet Brings Activism to Those Living with Mental Illness in Bew “Mental Health Awareness” Campaign 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Muscle Spasm Therapeutic Development Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... , ALEXANDRIA, Va., July 17 ... a regular basis, and 40% of community-dwelling seniors take five or ... unemployment, many people are looking for ways to save on prescription ... for Medicines & Healthy Aging(C) (CMHA) -- a consumer-focused resource developed ...
... , Non and for profit collaborate during tough economic ... Nonprofits stressing over the sinking economy are thinking out of the ... companies are struggling much in the same way except that their funding ... & Family Health (ICFH) and Jungle Island decided to collaborate to attract ...
... ... with One Healthcare Solution,s EMR system in medical practices , ... Georgetown, TX (PRWEB) July 17, 2009 -- ... announced the signing of a Software Distribution Agreement along with an Additional Services Agreement ...
... The YAI/National ... at the law firm of Loeb & Loeb LLP, as Chair, and Sheldon Kwiat, President of ... ... Institute for People with Disabilities (YAI/NIPD) Board of Trustees has elected Eliot Green, a Partner ...
... ... a featured expert on searchbodydetox.com, a new informational Web site devoted to all aspects of ... ... of the alternative health movement, is now a featured expert on searchbodydetox.com , a ...
... how to pay for an overhaul of the nation,s health ... that including both private and public insurance choices in ... much as $265 billion in administrative costs from 2010 to ... budget costs of health care reform legislation under $1 trillion. ...
Cached Medicine News:Health News:Center for Medicines & Healthy Aging(C) and BidRx(R) Partner to Help Consumers Save on Prescription Medications 2Health News:Center for Medicines & Healthy Aging(C) and BidRx(R) Partner to Help Consumers Save on Prescription Medications 3Health News:Fundraising in the Jungle 2Health News:One Healthcare Solution and MedBeyond Partner to Provide Optimum Solution for EMR and Medical Billing 2Health News:One Healthcare Solution and MedBeyond Partner to Provide Optimum Solution for EMR and Medical Billing 3Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 2Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 3Health News:YAI/NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 4Health News:Dr. Julian Whitaker Featured on Searchbodydetox.com 2Health News:Private and public insurance choices could help pay for national health care reform 2Health News:Private and public insurance choices could help pay for national health care reform 3
... Antibodies (ANAs) has long been an important ... diseases. The antigens used in their detection ... human or animal nuclei, this has led ... (ENAs). The most commonly measured ENA specifications ...
Enzyme-linked immunosorbent assays for the detection and quantitation of IgG antibodies to extractable nuclear antigens (ENA) Sm in human serum.Antibodies to Sm aid in the diagnosis of systemic lupus...
... assays for the detection and ... extractable nuclear antigens (ENA) SS-B ... (Ro) and SS-B (La) antibodies ... SLE, subacute cutaneous lupus erythematosus ...
... assays for the detection and ... extractable nuclear antigens (ENA)RNP, Sm ... Sm aid in the diagnosis ... ,RNP antibodies aid in the ...
Medicine Products: